Piramal Pharma to increase Stake to 100 percent in Convergence Chemicals

Published On 2020-10-30 07:00 GMT   |   Update On 2020-10-30 07:40 GMT

New Delhi: Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited (PEL), and Navin Fluorine International Limited (Navin Fluorine) have recently announced a mutual agreement to increase Piramal's stake in Convergence Chemicals Private Limited (CCPL) to 100% by buying out Navin Fluorine's 49% stake in CCPL at INR 65.10 crores. Recently, PEL transferred its entire...

Login or Register to read the full article

New Delhi: Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited (PEL), and Navin Fluorine International Limited (Navin Fluorine) have recently announced a mutual agreement to increase Piramal's stake in Convergence Chemicals Private Limited (CCPL) to 100% by buying out Navin Fluorine's 49% stake in CCPL at INR 65.10 crores.

Recently, PEL transferred its entire stake in CCPL to PPL. CCPL, incorporated in November 2014, develops and manufactures specialty fluorochemicals, primarily starting material required for PPL's anesthetics production.

As PPL continues to grow its anesthetics business, its resultant requirement for the starting material is expected to increase in the coming years.

Similarly, it is expected that Navin Fluorine will leverage the developed chemistry for growth in certain specialty chemical segments.

As a part of this arrangement, Navin Fluorine would obtain from PPL a perpetual license to use the technical knowhow for development and marketing of select products, and Navin Fluorine would continue to be a key raw material supplier to CCPL.

The Agreements are subject to customary regulatory closing conditions.

Read also: Tri-Activ Disinfectant Spray for multi-surface effective against Covid: Piramal Pharma




Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News